In Arizona, the statute of limitations for Reglan (metoclopramide) tardive dyskinesia lawsuits typically begins when the injury is discovered or should have been discovered. This period is generally two years from that date. However, laws vary, so consulting a qualified attorney is essential to understand your specific situation.
If you or a loved one has developed uncontrollable muscle movements after taking Reglan, you may be dealing with tardive dyskinesia. Decades of pharmacovigilance have established this condition as a known risk of prolonged metoclopramide use. This page explains the symptoms, typical onset timeline, and essential documentation steps.
Reglan (metoclopramide) is a prescription medication approved for short-term use in adults with symptomatic gastroesophageal reflux and diabetic gastroparesis. The drug carries a boxed warning from the U.S. Food and Drug Administration (FDA) stating that metoclopramide can cause tardive dyskinesia (TD), a potentially irreversible movement disorder. The risk of developing TD increases with longer treatment duration and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the FDA advises using the drug for the shortest possible duration, with periodic reassessment of the need for continued therapy. For gastroesophageal reflux, the maximum approved treatment duration is 12 weeks; for diabetic gastroparesis, treatment should also not exceed 12 weeks unless longer use is unavoidable, in which case routine monitoring for TD signs is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. These movements can be disfiguring and may persist even after Reglan is discontinued. The FDA label notes that metoclopramide can suppress or partially suppress TD signs, potentially delaying diagnosis by masking the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway linking Reglan to TD involves dopamine receptor blockade in the basal ganglia, which can lead to supersensitivity of dopamine receptors and subsequent abnormal motor control. This effect is dose- and duration-dependent, with longer exposure increasing the likelihood of permanent neurological damage.
For patients in Arizona who have developed TD after using Reglan, the statute of limitations is a critical factor in pursuing legal claims. Arizona law generally requires that a lawsuit for personal injury be filed within two years from the date the injury is discovered or reasonably should have been discovered. In the context of Reglan-induced TD, the timeline between exposure and documented harm can be complex. TD may develop months or years after starting Reglan, and symptoms can be subtle initially, such as mild tongue protrusions or lip smacking. The FDA label warns that TD can be delayed in diagnosis because metoclopramide may mask early signs (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Therefore, the 'discovery' date for statute of limitations purposes may be when a physician formally diagnoses TD or when the patient becomes aware of the link between their symptoms and Reglan use. Settlement considerations for affected patients hinge on several factors. First, the adequacy of warnings is a central issue. The FDA boxed warning clearly states the risk of TD and the need for short-term use, but many patients were prescribed Reglan for extended periods, sometimes years, without proper monitoring. The label explicitly states that Reglan is not recommended for pediatric patients due to TD risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397), yet off-label use in children has occurred. Second, the severity and irreversibility of TD symptoms affect settlement value. Patients with persistent, disabling movements may have higher compensation for medical expenses, lost wages, and pain and suffering. Third, the duration of Reglan use and cumulative dosage are key evidence points. The FDA warns that risk increases with total cumulative dose (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397), so patients who took Reglan for longer than 12 weeks have a stronger case for inadequate monitoring. In Arizona, patients must also consider whether their claim is against the manufacturer for failure to warn or against a healthcare provider for negligent prescribing. The statute of limitations may differ for medical malpractice claims, which often have a two-year limit from the date of injury or discovery. Given the latency of TD, patients should seek legal counsel promptly to preserve their rights. Settlement amounts in Reglan TD cases have varied widely, with some reaching hundreds of thousands of dollars depending on the severity of symptoms and the strength of evidence linking the drug to the injury.
In summary, Reglan carries a clear FDA warning about TD risk, but many patients were exposed beyond recommended durations. For Arizona patients, the statute of limitations typically runs two years from discovery of the injury. Settlement considerations include the adequacy of warnings, duration of use, and severity of TD. Patients should consult an attorney experienced in pharmaceutical litigation to evaluate their specific circumstances. References - https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Arizona, the statute of limitations for personal injury claims, including those related to Reglan-induced tardive dyskinesia, is generally two years from the date the injury is discovered or reasonably should have been discovered. This discovery date may be when a physician formally diagnoses TD or when the patient becomes aware of the link between their symptoms and Reglan use.
Settlement value depends on the adequacy of warnings, duration of Reglan use, cumulative dosage, severity and irreversibility of TD symptoms, and whether the claim is against the manufacturer or healthcare provider. Patients with prolonged use beyond 12 weeks and disabling symptoms may have stronger cases.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.